Literature DB >> 19539259

Characterization of post-operative risk associated with prior drug-eluting stent use.

Saif Anwaruddin1, Arman T Askari, Hammad Saudye, Lilian Batizy, Penny L Houghtaling, Mohammad Alamoudi, Michael Militello, Kamran Muhammad, Samir Kapadia, Stephen G Ellis.   

Abstract

OBJECTIVES: The aim of this study was to assess risk of inpatient surgery at any time after percutaneous coronary intervention (PCI) with drug-eluting stents (DES).
BACKGROUND: Risk of adverse events, including stent thrombosis (ST), in patients undergoing surgical procedures with prior DES remains poorly defined.
METHODS: Outcomes of consecutive patients having inpatient surgical procedures after PCI with DES, placed from April 28, 2003 until December 31, 2006 at a tertiary-care medical center, were studied. Primary and secondary end points were 30-day post-operative risk of the Academic Research Consortium (ARC) definite and modified probable definitions of ST and combined 30-day post-operative risk of death, nonfatal myocardial infarction (MI), or ST, respectively. Multivariable logistic regression analyses were used to determine independent risk factors.
RESULTS: Six hundred six inpatient surgeries on 481 patients with a mean time from PCI to surgery of 1.07 +/- 0.89 years were evaluated. The primary and secondary end points occurred after 11 (2.0%) and 56 (9%) surgeries, respectively. Risk of the combined end point and ST decreased significantly in the first 1 to 6 months after PCI (p < 0.0001 and p < 0.014, respectively); however, risk persisted when time between PCI and surgery was >12 months. Independent correlates of the combined end point include emergency surgery, antecedent MI, the pre-operative use of intravenous heparin, and atherosclerotic lesion length treated with DES. Oral antiplatelet status at time of surgery was not a correlate of events.
CONCLUSIONS: Risk of 30-day post-operative adverse events, including ST, remains significantly higher when surgery is performed soon after PCI, while intermediate-term risk extending at least 2 to 3 years remains important.

Entities:  

Mesh:

Year:  2009        PMID: 19539259     DOI: 10.1016/j.jcin.2009.03.014

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  13 in total

1.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Surgery after drug-eluting stent implantation: it's not all doom and gloom!

Authors:  Francesco Saia
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 3.  Bridge with intravenous antiplatelet therapy during temporary withdrawal of oral agents for surgical procedures: a systematic review.

Authors:  Nuccia Morici; Lorenzo Moja; Valentina Rosato; Alice Sacco; Antonio Mafrici; Silvio Klugmann; Maurizio D'Urbano; Carlo La Vecchia; Stefano De Servi; Stefano Savonitto
Journal:  Intern Emerg Med       Date:  2014-01-14       Impact factor: 3.397

Review 4.  Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management.

Authors:  Davide Cao; Rishi Chandiramani; Davide Capodanno; Jeffrey S Berger; Matthew A Levin; Mary T Hawn; Dominick J Angiolillo; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2020-08-05       Impact factor: 32.419

5.  Risks of noncardiac surgery early after percutaneous coronary intervention.

Authors:  Nathaniel R Smilowitz; Jeffrey Lorin; Jeffrey S Berger
Journal:  Am Heart J       Date:  2019-07-22       Impact factor: 4.749

6.  The safe and risk assessment of perioperative antiplatelet and anticoagulation therapy in inguinal hernia repair, a systematic review.

Authors:  Junsheng Li; Minggang Wang; Tao Cheng
Journal:  Surg Endosc       Date:  2019-07-15       Impact factor: 4.584

7.  Incidence, nature, and temporal trends of adverse events associated with noncardiac procedures among veterans with drug-eluting coronary artery stents.

Authors:  Charles Salters; Bruce Bradley; Richard J Charnigo; Zaman Shah; John Meehan; Ahmed Abdel-Latif; Khaled M Ziada
Journal:  Catheter Cardiovasc Interv       Date:  2015-05-06       Impact factor: 2.692

8.  Coronary artery disease: to cath or not to cath? When and how best to cath: those are the remaining questions.

Authors:  Roberta Rossini; Giuseppe Musumeci; Eliano Pio Navarese; Giuseppe Tarantini
Journal:  Am J Cardiovasc Dis       Date:  2013-02-17

9.  Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Maurizio Giuseppe Abrignani; Marco Ambrosetti; Nadia Aspromonte; Gabriella Barile; Roberto Caporale; Giancarlo Casolo; Emilia Chiuini; Andrea Di Lenarda; Pompilio Faggiano; Domenico Gabrielli; Giovanna Geraci; Alessio Gaetano La Manna; Aldo Pietro Maggioni; Alfredo Marchese; Ferdinando Maria Massari; Gian Francesco Mureddu; Giuseppe Musumeci; Federico Nardi; Antonio Vittorio Panno; Roberto Franco Enrico Pedretti; Massimo Piredda; Enrico Pusineri; Carmine Riccio; Roberta Rossini; Fortunato Scotto di Uccio; Stefano Urbinati; Ferdinando Varbella; Giovanni Battista Zito; Leonardo De Luca
Journal:  Eur Heart J Suppl       Date:  2018-05-31       Impact factor: 1.803

Review 10.  Bridging antiplatelet therapy in patients requiring cardiac and non-cardiac surgery: from bench to bedside.

Authors:  Davide Capodanno; Corrado Tamburino
Journal:  J Cardiovasc Transl Res       Date:  2013-11-23       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.